Guangdong Kanghua Healthcare Co., Ltd. Class H (3689) AI Stock Analysis

• Market Cap: HK$635.35M
• Dividend Yield: 8.42%
• Average Volume (3M): 1.58K
• Price to Earnings (P/E): 7.7
• Beta (1Y): 0.02
• Revenue Growth: 0.47%
• EPS Growth: 50.46%
• Country: HK
• Employees: 4,320
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.13
• Shares Outstanding: 84,394,000
• 10 Day Avg. Volume: 40
• 30 Day Avg. Volume: 1,580
• PEG Ratio: -0.57
• Price to Book (P/B): 0.53
• Price to Sales (P/S): 0.37
• P/FCF Ratio: 3.97
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 71 Outperform
• Price Target: HK$2.00 ▲(1.01% Upside)

The overall stock score of 71 reflects a strong valuation with a low P/E ratio and high dividend yield, making it attractive for value and income investors. However, technical indicators suggest some caution due to bearish momentum. Financial performance is mixed, with strong cash flow but declining profitability margins, which could impact long-term growth.

Guangdong Kanghua Healthcare Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Guangdong Kanghua Healthcare Co., Ltd. is a leading player in the healthcare industry, primarily focused on the research, development, and production of high-quality medical devices and healthcare products. The company operates in several sectors, including medical imaging, diagnostics, and rehabilitation equipment, catering to both domestic and international markets. Its core offerings include advanced medical instruments, health monitoring devices, and innovative solutions aimed at improving patient care and outcomes.

How the Company Makes Money

Guangdong Kanghua Healthcare generates revenue through multiple streams, primarily by selling its medical devices and healthcare products to hospitals, clinics, and healthcare facilities. The company benefits from strong demand for its products due to the growing emphasis on healthcare quality and efficiency. Additionally, it may engage in long-term contracts with healthcare institutions, which provide a stable source of income. Key partnerships with research institutions and collaborations with technology firms also enhance its product offerings, helping to drive sales. The company may also explore export opportunities, broadening its market reach and contributing to its earnings.

Guangdong Kanghua Healthcare Co., Ltd. Class H Financial Statement Overview

Summary

Guangdong Kanghua Healthcare Co., Ltd. demonstrates solid cash flow performance, which is a positive indicator for liquidity and operational funding. However, declining profit margins and ROE raise concerns about long-term profitability and efficiency. While the balance sheet is strong with a solid equity base, the income statement suggests that the company may face challenges in maintaining profitability amid rising costs or competitive pressures.

Income Statement

The company exhibits stable revenue with a slight increase from the previous year, indicating consistent growth. Gross profit margin has decreased over the year from 17.84% to 15.65%, suggesting increased costs or competitive pricing pressures. Net profit margin is relatively low at 0.75%, declining from 5.93%, which raises concerns about profitability. The EBIT and EBITDA margins have also decreased, indicating reduced operational efficiency.

Balance Sheet

The company's debt-to-equity ratio remains manageable, indicating a stable capital structure. Return on equity is low at 1.07%, down from 8.50%, which may signal inefficiencies in generating returns for shareholders. The equity ratio stands strong at 52.50%, reflecting a solid equity base supporting the assets.

Cash Flow

The company has a strong free cash flow growth of 163.43%, suggesting robust cash generation capabilities. The operating cash flow to net income ratio is high, indicating strong cash flow relative to net income, enhancing financial flexibility. The free cash flow to net income ratio is also favorable, underscoring efficient cash utilization.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.05B	2.06B	2.04B	1.85B	1.95B	1.75B
Gross Profit	334.01M	321.87M	364.37M	261.35M	352.75M	263.15M
EBITDA	256.12M	224.86M	305.92M	233.79M	298.46M	138.79M
Net Income	76.52M	15.34M	121.06M	59.70M	94.31M	-25.37M
Balance Sheet
Total Assets	2.78B	2.74B	2.62B	2.72B	2.70B	2.45B
Cash, Cash Equivalents and Short-Term Investments	791.85M	678.40M	718.52M	754.34M	770.34M	584.67M
Total Debt	445.48M	320.66M	426.58M	429.92M	494.54M	465.82M
Total Liabilities	1.32B	1.28B	1.13B	1.22B	1.23B	1.05B
Stockholders Equity	1.45B	1.44B	1.42B	1.49B	1.43B	1.33B
Cash Flow
Free Cash Flow	340.37M	193.15M	73.31M	106.20M	162.19M	27.75M
Operating Cash Flow	378.11M	280.13M	204.19M	221.40M	333.37M	275.29M
Investing Cash Flow	-48.17M	-87.33M	-107.72M	-83.16M	-299.33M	-182.15M
Financing Cash Flow	-76.14M	-251.71M	-55.56M	-110.88M	23.27M	-138.22M

Guangdong Kanghua Healthcare Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.98
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3689, the sentiment is Negative. The current price of 1.98 is above the 20-day moving average (MA) of 1.96, below the 50-day MA of 2.00, and above the 200-day MA of 1.89, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 34.80 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3689.

Guangdong Kanghua Healthcare Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0722	78 Outperform	HK$372.44M	11.68	4.28%	7.31%	-2.88%	-22.83%
3689	71 Outperform	HK$635.35M	7.70	5.33%	8.42%	0.47%	50.46%
1518	64 Neutral	HK$395.36M	―	-8.40%	2.76%	-21.31%	-149.92%
9906	57 Neutral	HK$966.00M	78.16	1.87%	―	-13.22%	-69.35%
3869	56 Neutral	HK$827.78M	5.69	30.40%	―	2.30%	―
1419	55 Neutral	HK$311.23M	11.82	3.40%	3.41%	9.07%	8.95%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Guangdong Kanghua Healthcare Co., Ltd. Class H Corporate Events

Guangdong Kanghua Healthcare Announces Board Changes

Guangdong Kanghua Healthcare Group Co., Ltd. announced a change in its board of directors, with Mr. Lv Yubo resigning as a non-executive director to focus on other endeavors, and Mr. Jiang Xiwen being appointed as his replacement effective October 17, 2025. Mr. Jiang, a well-credentialed professional with a background in microbiology and leadership roles in medical device associations, will bring his expertise to the company, potentially impacting its strategic direction and stakeholder relations positively.

The most recent analyst rating on (HK:3689) stock is a Buy with a HK$2.00 price target. To see the full list of analyst forecasts on Guangdong Kanghua Healthcare Co., Ltd. Class H stock, see the HK:3689 Stock Forecast page.

Guangdong Kanghua Healthcare Announces Board Composition

Guangdong Kanghua Healthcare Co., Ltd. has announced the composition of its board of directors, detailing the roles and functions of each member. This announcement highlights the company’s governance structure, which includes executive, non-executive, and independent non-executive directors, as well as their participation in various board committees, potentially impacting the company’s strategic decisions and stakeholder relations.

The most recent analyst rating on (HK:3689) stock is a Buy with a HK$2.00 price target. To see the full list of analyst forecasts on Guangdong Kanghua Healthcare Co., Ltd. Class H stock, see the HK:3689 Stock Forecast page.

Guangdong Kanghua Healthcare Reports Turnaround with Interim Profit

Guangdong Kanghua Healthcare Group Co., Ltd. reported its interim results for the six months ending June 30, 2025, showing a slight revenue decrease of 0.3% to RMB981.5 million compared to the same period in 2024. Despite the revenue dip, the company turned around its financial performance with a profit of RMB32.6 million, a significant improvement from a loss of RMB24.7 million in the previous year. The adjusted EBITDA saw a notable increase of 38.7% to RMB126.7 million, reflecting improved operational efficiency. However, the Board decided not to recommend an interim dividend for this period.

The most recent analyst rating on (HK:3689) stock is a Buy with a HK$2.00 price target. To see the full list of analyst forecasts on Guangdong Kanghua Healthcare Co., Ltd. Class H stock, see the HK:3689 Stock Forecast page.

Guangdong Kanghua Healthcare Reports Profit Turnaround for 2025 Interim

Guangdong Kanghua Healthcare Group Co., Ltd. announced a significant turnaround in its financial performance for the first half of 2025, expecting a profit of RMB32.0 million to RMB33.0 million compared to a loss of RMB24.7 million in the same period of 2024. This improvement is primarily due to the disposal of a 55% equity interest in Kangxin Hospital, which resulted in a gain of approximately RMB19.5 million. The de-consolidation of Kangxin Hospital’s financial results, which had been loss-making, contributed positively to the Group’s overall financial health.

The most recent analyst rating on (HK:3689) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Guangdong Kanghua Healthcare Co., Ltd. Class H stock, see the HK:3689 Stock Forecast page.

Guangdong Kanghua Healthcare Schedules Board Meeting for Interim Results and Dividend Consideration

Guangdong Kanghua Healthcare Group Co., Ltd. has announced that its board of directors will meet on August 29, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the potential payment of an interim dividend, which may impact the company’s financial standing and shareholder returns.

The most recent analyst rating on (HK:3689) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Guangdong Kanghua Healthcare Co., Ltd. Class H stock, see the HK:3689 Stock Forecast page.